Publications by authors named "Howard Mackey"

Claim this Profile
E
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Susanne Ostrowitzki, Tobias Bittner, Kaycee M Sink, Howard Mackey, Christina Rabe

JAMA Neurol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Power and sample size for random coefficient regression models in randomized experiments with monotone missing data.
Nan Hu, Howard Mackey, Ronald Thomas

Biom J· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.
Silvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, Nan Hu, Qinshu Lian, Howard Mackey

Alzheimers Dement· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.
Pierre N Tariot, Francisco Lopera, Jessica B Langbaum, Ronald G Thomas, Suzanne Hendrix, Howard Mackey

Alzheimers Dement (N Y)· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010.
Mary Nguyen-Nielsen, Lisa Wang, Lars Pedersen, Anne Braae Olesen, Jeannie Hou, Howard Mackey

Eur J Dermatol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An industry statistician's perspective on PHC drug development.
Jane Fridlyand, Ru-Fang Yeh, Howard Mackey, Thomas Bengtsson, Paul Delmar

Contemp Clin Trials· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sample size and threshold estimation for clinical trials with predictive biomarkers.
Howard M Mackey, Thomas Bengtsson

Contemp Clin Trials· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Jordan Berlin, Johanna C Bendell, Lowell L Hart, Irfan Firdaus, Ira Gore, Howard M Mackey

Clin Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Aleksandar Sekulic, Michael R Migden, Anthony E Oro, Luc Dirix, Karl D Lewis, Howard M Mackey

N Engl J Med· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
Daniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, Josina C Reddy, Robert L Yauch, Howard M Mackey

N Engl J Med· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Some notable properties of the standard oncology Phase I design.
Gregory J Hather, Howard Mackey

J Biopharm Stat· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Stephen A Cannistra, Ursula A Matulonis, Richard T Penson, Julie Hambleton, Jakob Dupont, Howard Mackey

J Clin Oncol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis